Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Monday, July 6th. The stock was sold at an average price of $548.96, for a total value of $5,215,120.00. Following the sale, the chief executive officer owned 40,513 shares in the company, valued at $22,240,016.48. This trade represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

United Therapeutics Stock Up 2.0%

UTHR stock traded up $10.74 during midday trading on Tuesday, hitting $557.99. The company’s stock had a trading volume of 120,736 shares, compared to its average volume of 494,100. The stock has a market cap of $23.69 billion, a price-to-earnings ratio of 20.60, a PEG ratio of 1.82 and a beta of 0.58. The stock’s 50-day moving average price is $557.83 and its 200 day moving average price is $528.36. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period in the prior year, the business earned $6.63 earnings per share. As a group, equities analysts forecast that United Therapeutics Corporation will post 26.63 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on UTHR. Cantor Fitzgerald lifted their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. Bank of America lifted their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. HC Wainwright upped their price objective on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Finally, Morgan Stanley set a $516.00 target price on United Therapeutics in a research report on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $619.42.

Institutional Trading of United Therapeutics

A number of institutional investors have recently modified their holdings of the business. Torren Management LLC bought a new position in shares of United Therapeutics in the fourth quarter worth $26,000. Activest Wealth Management grew its position in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares in the last quarter. WealthCollab LLC grew its position in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares in the last quarter. Rakuten Securities Inc. increased its stake in United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the last quarter. Finally, Entrust Financial LLC purchased a new stake in shares of United Therapeutics in the 4th quarter valued at about $31,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.